arrow
J

Javier Muñoz

Mayo Clinic
H指数:44
被引数:1.9万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Mantle cell lymphoma outcomes following sequential first-line bendamustine-rituximab and second-line Bruton’s tyrosine kinase inhibitor therapy

套细胞淋巴瘤在序贯一线 bendamustine-rituximab 和二线 Bruton 酪氨酸激酶抑制剂治疗后的预后

2026-04-250
OAAI
Epcoritamab Plus Gemcitabine and Oxaliplatin Versus Rituximab Plus Gemcitabine and Oxaliplatin in Transplant-Ineligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Match-Adjusted Comparative Analysis

Epcoritamab 联合吉西他滨和奥沙利铂与利妥昔单抗联合吉西他滨和奥沙利铂在移植不适宜的复发/难治性弥漫大B细胞淋巴瘤中的应用:一项匹配调整后的比较分析

2025-10-130
OAAI
Multi-Institutional Study of ALK-Positive Large B-Cell Lymphoma: Outcomes in the Era of ALK Inhibitors and Biologically Informed Therapies

多中心研究:ALK阳性大B细胞淋巴瘤:ALK抑制剂和生物学指导治疗时代的结局

2025-09-030
PRE
Treatment Patterns and Outcomes Following Progression of Disease Post-CAR-T Therapy in Relapsed or Refractory Mantle Cell Lymphoma: A Multicenter Analysis

CAR-T疗法后疾病进展的复发或难治性套细胞淋巴瘤患者的治疗方案与结局:一项多中心分析

BLOOD
IF23.1
2024-11-050
PRE
Golseek-1: A Phase 3, Double-Blind, Randomized Study Comparing the Efficacy and Safety of Golcadomide Plus R-CHOP Vs R-CHOP in Patients with Previously Untreated, High-Risk, Large B-Cell Lymphoma

Golseek-1:一项III期、双盲、随机研究,比较Golcadomide联合R-CHOP与R-CHOP在既往未治疗的高危大B细胞淋巴瘤患者中的有效性与安全性。

BLOOD
IF23.1
2024-11-050
PRE
Five-Year Outcomes of Patients (Pts) with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Treated with Brexucabtagene Autoleucel (Brexu-cel) in ZUMA-2 Cohorts 1 and 2

ZUMA-2研究队列1和2中接受Brexucabtagene autoleucel(Brexu-cel)治疗的复发/难治性套细胞淋巴瘤(R/R MCL)患者的五年结局

BLOOD
IF23.1
2024-11-050
PRE
MANTLE CELL, FOLLICULAR, WALDENSTROM'S, AND OTHER INDOLENT B CELL LYMPHOMAS: CLINICAL AND EPIDEMIOLOGICAL

套细胞、滤泡性、Waldenström's及其他惰性B细胞淋巴瘤:临床与流行病学

BLOOD
IF23.1
2024-11-050
PRE
Outcomes of patients with R/R B-cell NHL and limited (<5 sites) pre-CART disease bridged with or without radiotherapy

R/R b细胞NHL和有限 (<5个部位) CART前疾病的患者的预后,有或没有放疗

2024-09-130
OAAI
Comparisons of treatment outcomes of epcoritamab versus chemoimmunotherapy, polatuzumab-based regimens, tafasitamab-based regimens, or chimeric antigen receptor T-cell therapy, in third-line or later relapsed/refractory large B-cell lymphoma
2024-08-160
OAAI
Outcomes of subsequent antilymphoma therapies after second-line axicabtagene ciloleucel or standard of care in ZUMA-7

ZUMA-7二线axicabtagene ciloleucel或护理标准后后续抗淋巴瘤治疗的结果

2024-06-112
OAAI
Applying the EHA/EBMT grading for ICAHT after CAR-T: comparative incidence and association with infections and mortality

Car-t后将EHA/EBMT分级应用于ICAHT: 比较发病率以及与感染和死亡率的关联

2024-04-1010
OAAI
T-cell receptor repertoire changes associated with clinical response in patients with B-cell non-Hodgkin's lymphoma receiving CD19 CAR-T therapy
2024-03-221
PRE
Monocyte transcriptome profiles associated with clinical response in patients with B-cell non-Hodgkin's lymphoma receiving CD19-directed CAR-T therapy
2024-03-220
PRE